All In Biotech

Drug Trial Radar · NCT04940026

Study to Determine Absorption, Metabolism, and Excretion of [14C]-SAR439859, and to Assess Absolute Oral Bioavailability of Amcenestrant (SAR439859), in Healthy Post-menopausal Women

A Phase 1, Open-label, Single Center, One Period, One Sequence Study to Determine Absorption, Metabolism, and Excretion of a Single Oral Dose of Radiolabeled [14C]- SAR439859 and an Assessment of the Absolute Oral Bioavailability Using the Microdosing Technique in Healthy Post-menopausal Women

Last checked: Nov 20, 2026Latest source record: Sep 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

6

Actual

Start

Jun 15, 2021

Primary completion

Aug 19, 2021

Study completion Aug 19, 2021

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jun 25, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
Female only, from 40 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Primary Objectives: * To assess the excretion balance after oral and IV administration of \[14C\]-SAR439859 * To assess PK of total radioactivity, \[14C\] -SAR439859 and its metabolite (M7) after IV administration of \[14C\]-SAR439859 and, PK of radioactivity, SAR439859 and M7 after oral administration of SAR439859 alone or with \[14C\]-SAR439859 * To assess IV clearance and absolute bioavailability of SAR439859 using microdose of \[14C\]-SAR439859 tracer on top of a single tablet oral dose. * To assess relative bioavailability of SAR439859 given as tablet or solution Secondary objectives: * To collect samples in order to assess metabolic profile in plasma and excreta of SAR439859 after oral administration of \[14C\]-SAR439859 as solution, contribution in plasma of SAR439859 and metabolite relative to total radioactivity and identify metabolites (samples will be analyzed according to metabolic analysis plan and results will be documented in a separate report). * To assess safety and tolerance of SAR439859

Conditions

  • Breast Cancer
  • Healthy Volunteers

Interventions

  • amcenestrantDrug

    Tablet Oral

  • [14C]-SAR439859 microtracerDrug

    Solution for infusion Intravenous

  • [14C]-SAR439859Drug

    Powder for oral solution Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of radioactive dose, SAR439859 and M7 excreted in urine and feces after IV administrationTime frame: Day 1 to Day 6
  2. Percentage of radioactive dose excreted in urine and feces after oral administrationTime frame: Day 7 up to max Day 44
  3. Assessment of Pharmacokinetic (PK) parameter: AUC for radioactivity and SAR439859 after IV administrationTime frame: Day 1 to Day 3
  4. Assessment of PK parameter: t1/2z for radioactivity and SAR439859 after IV administrationTime frame: Day 1 to Day 3
  5. Assessment of PK parameter: CL for SAR439859 after IV administrationTime frame: Day 1 to Day 3
  6. Assessment of PK parameter: AUC ratios after IV administrationTime frame: Day 1 to Day 3
  7. Assessment of PK parameter: Cmax for radioactivity and SAR439859 after oral administrationTime frame: Day 1 to Day 5, Day 7 to Day 11
  8. Assessment of PK parameter: tmax for radioactivity and SAR439859 after oral administrationTime frame: Day 1 to Day 5, Day 7 to Day 11
  9. Assessment of PK parameter: AUC for radioactivity and SAR439859 after oral administrationTime frame: Day 1 to Day 5, Day 7 to Day 11
  10. Assessment of PK parameter: t1/2z for radioactivity and SAR439859 after oral administrationTime frame: Day 1 to Day 5, Day 7 to Day 11
  11. Assessment of PK parameter: AUC ratios after oral administrationTime frame: Day 7 to Day 11
  12. Assessment of PK parameter: Cmax for M7 after IV and oral administrationTime frame: Day 1 to Day 5, Day 7 to Day 11
  13. Assessment of PK parameter: AUC for M7 after IV and oral administrationTime frame: Day 1 to Day 5, Day 7 to Day 11
  14. Assessment of PK parameter: t1/2z for M7 after IV and oral administrationTime frame: Day 1 to Day 5, Day 7 to Day 11
  15. Assessment of PK parameter: Rmet Cmax after IV and oral administrationTime frame: Day 1 to Day 5, Day 7 to Day 11
  16. Assessment of PK parameter: Rmet AUC after IV and oral administrationTime frame: Day 1 to Day 5, Day 7 to Day 11
  17. Absolute oral bioavailability of SAR439859Time frame: Day 1 to Day 5, Day 7 to Day 11
  18. Relative bioavailability of SAR439859 after oral administrationTime frame: Day 1 to Day 5, Day 7 to Day 11

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Investigational Site Number 8260001

    Nottingham, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.